The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age

Journal of Translational Medicine 2026 Open access

Read full text
Authors: Lucrezia Tuosto, Alain Jonathan Gelibter, Lidia Strigari, Angela Asquino, Marco Siringo, Angelica Pace, Flavio Valentino, Davide Capozzi, Serena Bianchini, Filippo Bellati, Daniele Santini, Marianna Nuti
+3 more Ilaria Grazia Zizzari, Aurelia Rughetti, Chiara Napoletano
DOI: 10.1186/s12967-026-07719-9
Cited by: 1
References: 34

Abstract

BACKGROUND: Over the past decade, the number of elderly cancer patients has increased, including those with NSCLCs, most of whom are over 60 years old. NSCLC patients receive anti-PD1-based therapies. These therapies directly target the immune system by activating T cells. However, older patients exhibit several baseline immune system changes compared to their younger counterparts, which could affect treatment effectiveness. This study aims to assess the immune systems of younger (

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Multiple and Secondary Primary Cancers

Publication details

Journal / source
Journal of Translational Medicine
Publisher
Springer Science and Business Media LLC
Volume
24
Issue
1
Publication date
14 February 2026
Language
EN